Esperion Therapeutics (NASDAQ: ESPR) announced the appointment of Scott Braunstein, M.D. as a Class III Director, with a term expiring ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Changes Management Comments

Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of DirectorsJune 15, 2015 8:30 AM Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - BarclaysJune 11, 2015 2:21 PM